Foresite Capital

Foresite Capital is an American venture capital and growth equity firm headquartered in San Francisco.[1][2] As of May 2019, the company had raised four funds: Foresite Capital Fund I, II, III and IV.[1][3]

Foresite Capital
TypePrivate
IndustryVenture capital, growth equity
Founded2011
FounderJim Tananbaum, CEO
Headquarters
San Francisco
,
United States
Area served
Worldwide
Websitewww.foresitecapital.com

History

Foresite Capital was founded in 2011 by Jim Tananbaum, co-founder of Theravance, who became CEO of the company.[4][5][6] Foresite Capital raised its $100 million Fund I in 2013.[7][8][6] In 2014, Foresite Capital closed Foresite Capital Fund II, a $300 million fund.[9] Foresite Capital Fund III, a $450 million fund, was closed in July 2015.[9] Foresite Capital Fund IV, a $668 million fund, closed in March 2018.[10]

Investments

Foresite Capital funded 10x Genomics since its Series A round in November 2013 and led its Series B round in January 2015, as well as its Series C round in March 2016.[11][12] Foresite Capital has invested in companies such as Acceleron Pharma, Aimmune, ALX Oncology, Aerie Pharmaceuticals,[13] Ascendis, Blueprint Medicines, Color Genomics, CueHealth, Cytokinetics, DNAnexus,[14] Editas Medicine,[15] Eikon Therapeutics, Epizyme,[1] Evonetix, Intarcia Therapeutics,[16][17] Inscripta,[18] Immunomedics,[19][20] Intellia Therapeutics,[21] Juno Therapeutics,[22] Karyopharm, Keryx, Kura Oncology, Keros Therapeutics, Maze Therapeutics, MyoKardia, MyOme, Natera,[19] Nurix, Olema Oncology, Orexigen,[23] Pacific Biosciences,[24] Peloton Therapeutics, Pharvaris, MindStrong Health, Quantum-SI, Relay Therapeutics,[25] Insitro,[26] HealthVerity, Turning Point Therapeutics, Element Biosciences,[27] Portola Pharmaceuticals, Universal American, Xencor, and WaveTech, in addition to 10x Genomics.[28]

Leadership

Foresite Capital is led by Midas List honoree Jim Tananbaum along with managing directors Matt Buten, Alisa Mall,[29] Dorothy Margolskee, Michael Rome, Dennis Ryan, and Vikram Bajaj.[30][31]

References
  1. David Holley (29 July 2015). "Foresite Capital Keeps Late-Stage Healthcare Focus With $450M Third Fund". Xconomy. Retrieved 20 May 2017.
  2. Brian Gormley (31 January 2013). "Growth-Equity Firm Foresite Capital Raises $100M for Debut Health-Care Fund". Wall Street Journal. Retrieved 20 May 2017.
  3. "Foresite Capital launchew new venture capital fund worth $668 million". Biospace. Retrieved 21 June 2019.
  4. Damian Garde (29 July 2015). "Foresite Capital reloads with a $450M biotech venture fund". Fierce Biotech. Retrieved 20 May 2017.
  5. "Foresite Capital raises $100M to invest in late-stage healthcare companies". San Francisco Business Times. 31 January 2013. Retrieved 20 May 2017.
  6. Eric Blattberg (1 April 2014). "Health care venture firm Foresite Capital closes $300M fund". Venture Beat. Retrieved 20 May 2017.
  7. Ben Fidler (6 November 2013). "Karyopharm Prices Upsized IPO at $16 Per Share, Begins Trading Today". Xconomy. Retrieved 20 May 2017.
  8. Luke Timmerman (31 January 2013). "Foresite Capital Closes $100M Fund for Late-Stage Biotechs". Xconomy. Retrieved 20 May 2017.
  9. Damian Gards (1 April 2014). "Foresite banks $300M to bet on late-stage biotechs". Fierce Biotech. Retrieved 20 May 2017.
  10. "Venture fund Foresite Capital raises largest-ever $668m fund". Mass Device. Retrieved 19 June 2019.
  11. Nick Paul Taylor (21 March 2016). "10X Genomics scoops another $55M to fuel commercialization of long-read tech". Fierce Biotech. Retrieved 20 May 2017.
  12. Alex Lash (12 January 2015). "10X Genomics Emerges With $80M and Toaster-Sized Sequencer Upgrade". Xconomy. Retrieved 20 May 2017.
  13. Ed Lin (14 October 2016). "Aerie Stock Hits Record High, Holder Sells $2 Million". Barrons. Retrieved 20 May 2017.
  14. "Foresite Capital". Crunchbase. Retrieved 2019-05-02.
  15. "Foresite Capital - Massinvestor Venture Capital and Private Equity Database". massinvestordatabase.com. Retrieved 2019-02-27.
  16. Dan Primack (15 September 2016). "Diabetes 'Unicorn' Raises Final VC Round Before IPO". Fortune. Retrieved 20 May 2017.
  17. "Here's who stands to gain from Intarcia's success with a type 2 diabetes pump". Boston Business Journal. 2 October 2014. Retrieved 20 May 2017.
  18. "Muse Bio Closes $23M Series B Financing Round". Genome Web. Retrieved 20 May 2017.
  19. "FORESITE CAPITAL MANAGEMENT III, LLC Institutional Portfolio". NASDAQ.com. Retrieved 2019-05-02.
  20. "Intarcia Therapeutics Venture Capital and Private Equity Financings". www.vcnewsdaily.com. Retrieved 2019-02-27.
  21. "Foresite Capital". Crunchbase. Retrieved 2019-05-02.
  22. "Foresite Capital reloads with a $450M biotech venture fund". FierceBiotech. Retrieved 2019-05-02.
  23. "Xconomy: Foresite Capital Reloads With New $300M Late-Stage Biotech Fund". Xconomy. 2014-04-01. Retrieved 2019-05-14.
  24. Timmerman, Luke. "Stealthy 10X Genomics Raises $55.5M To Beef Up DNA Sequencing". Forbes. Retrieved 2019-05-14.
  25. "Relay Therapeutics hits VC jackpot with $400M series C round for protein-motion drug discovery". Med City News. Retrieved 19 June 2019.
  26. "Backed by big-name VCs, this startup is turning machine learning on drug discovery". The Business Journals. Retrieved 19 June 2019.
  27. "Element Biosciences Lands $15M to Develop New Genetic Analysis Tools". Xconomy. Retrieved 21 June 2019.
  28. "Foresite Capital Management Iv, Llc - Latest 13F Holdings - Fintel.io". fintel.io. Retrieved 2019-05-14.
  29. "Heir Apparent at Carnegie Corp. Exits for Biotech Venture Firm". Institutional Investor. Retrieved 18 December 2020.
  30. "A life sciences firm run by a top VC and a cofounder of Alphabet's life sciences arm, just raised its biggest fund yet". TechCrunch. Retrieved 19 June 2019.
  31. "Nine VCs who matter but you never read about". Knect365. Retrieved 19 June 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.